870 related articles for article (PubMed ID: 32485838)
1. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.
Fujii H; Kawada N; Japan Study Group Of Nafld Jsg-Nafld
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485838
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
4. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
5. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
6. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
8. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
11. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
13. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
16. Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.
Dichtel LE; Cordoba-Chacon J; Kineman RD
J Clin Endocrinol Metab; 2022 Jun; 107(7):1812-1824. PubMed ID: 35172328
[TBL] [Abstract][Full Text] [Related]
17. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
18. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
19. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
20. Modifiers of Liver-Related Manifestation in the Course of NAFLD.
Nasr P; Blomdahl J; Kechagias S; Ekstedt M
Curr Pharm Des; 2020; 26(10):1062-1078. PubMed ID: 32156227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
